Prime Medicine, Inc.
Prime Medicine, Inc. (PRME): 12 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
10.2 months
D/E 2.84 · 0% dilution
Lead: Phase 3
12 candidates
1 upcoming, next in ~348d
N/A
A transparent, data-derived signal for Prime Medicine, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$512.1M
Cash
$77.8M
Quarterly Burn
$42.7M
Runway
10.2 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| booster vaccination | Phase 3 |
| cystic fibrosis program | Preclinical |
| ex vivo t-cell therapeutic products | Preclinical |
| friedreich's ataxia program | Preclinical |
| gsd1b program | Preclinical |
| next generation ex vivo t-cell therapies | Preclinical |
| pm359 | Phase 1/Phase 2 |
| pm577 | Preclinical |
| pm647 | Preclinical |
| prime edited scip | Preclinical |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
187
Total value held
$258.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 8,948,324 | $31.1M |
| blackrock, inc. | 8,501,708 | $29.6M |
| state street corp | 6,345,125 | $22.1M |
| ark investment management llc | 6,246,827 | $21.7M |
| balyasny asset management l.p. | 4,123,365 | $14.3M |
| sumitomo mitsui trust group, inc. | 2,940,793 | $10.2M |
| amova asset management americas, inc. | 2,940,793 | $10.2M |
| ubs group ag | 2,888,418 | $10.1M |
| geode capital management, llc | 2,743,700 | $9.6M |
| adar1 capital management, llc | 1,973,282 | $6.9M |
Showing top 10 of 187 institutional holders of Prime Medicine, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Prime Medicine, Inc.'s pipeline?
Prime Medicine, Inc. (PRME) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Prime Medicine, Inc.'s lead drug candidate?
Prime Medicine, Inc.'s most advanced tracked candidate is booster vaccination (Phase 3) for Rabies (Healthy Volunteers).
What is Prime Medicine, Inc.'s next catalyst?
Prime Medicine, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicentre, Open-label Trial in Healthy Volunteers to Assess the Boostability of Three Different " — expected June 1, 2027.
What is Prime Medicine, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Prime Medicine, Inc. has approximately 10.2 months of cash runway.
What is Prime Medicine, Inc.'s market capitalization?
Prime Medicine, Inc.'s market capitalization is approximately $512.1M.
Get the full picture on Prime Medicine, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.